Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 467Neoplasms 315Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 207Lung Neoplasms 176Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 59Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Interventions

nabiximols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Marijuana Abuse × Clear all
NCT02073474 2022-12-20

An Observational Post-Marketing Safety Registry of Sativex®

Jazz Pharmaceuticals

Completed
978 enrolled

Marijuana Abuse, Diabetes Mellitus, Multiple Sclerosis, Neoplasms, Neuralgia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡